Nanotechnology in Medicine

Name: Nanotechnology in Medicine | Toxicity and Safety
Brand: Jossey-Bass
Price: 139.99 EUR
Availability: OnlineOnly

Toxicity and Safety

Mahendra Rai Mrunali Patel Rashmin Patel(Herausgeber*in)

Jossey-Bass (Verlag)

1. Auflage

Erschienen am 19. Oktober 2021

448 Seiten

E-Book

PDF mit Adobe-DRM

Systemvoraussetzungen

978-1-119-76987-3 (ISBN)

139,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Inhalt

Cover
Title Page
Copyright Page
Contents
Preface
List of Contributors
List of Abbreviations
Part I Nanomedicine: Nanotoxicological Insights
Chapter 1 Nanomedicines: Applications and Toxicological Concerns
1.1 Introduction
1.2 Nanomedicine's Revolution
1.3 Potential Applications of Nanomedicine
1.3.1 Diagnosis
1.3.2 Drug Delivery
1.3.3 Tissue Engineering and Regenerative Medicine
1.4 Clinical Translation of Nanomedicine
1.5 Nanotoxicological Challenges
1.6 Safety Issues and Regulations
1.7 Conclusion and Future Perspectives
References
Chapter 2 Microbial Biopolymers and Their Derivatives as Nanotechnological Tools for Medicine: Applications, Advantages, Toxicity, and Safety
2.1 Introduction
2.2 Natural Polymers: Conceptualization, Classifications, and Physicochemical Characteristics
2.3 Applications of Biopolymers in Nanoparticles, Nanofibers, and Drug Delivery Systems of Therapeutic Importance
2.4 Safety of Microbial Biopolymers Used in Nanoscale-Systems for Therapeutic Applications
2.5 Conclusions
References
Part II Nanoparticles: Toxicity and Safety
Chapter 3 Selenium Nanoparticles: Toxicity and Safety
3.1 Introduction
3.2 Selenium Forms
3.3 Toxicity of Selenium Nanoparticles
3.4 Toxicity Mechanisms
3.5 Conclusion
References
Chapter 4 Impact of Nanoparticles on Protozoa
4.1 Introduction
4.1.1 Antiprotozoal Drugs
4.2 Nanosystems
4.2.1 Preparation and Synthesis of Nanoparticles and Systems
4.3 Nanosystems with Effect on Human Parasitic Protozoa
4.3.1 Malaria
4.3.2 Trypanosomiases
4.3.3 Leishmaniasis
4.3.4 Toxoplasmosis
4.3.5 Cryptosporidium
4.3.6 Acanthamoeba
4.4 Nanosystems with Effect on Veterinary Parasitic Protozoa
4.5 Nanomaterial Toxicity on Beneficial Protozoa
4.6 Conclusion
Acknowledgment
References
Chapter 5 Toxicity of Metallic Nanoparticles: A Pressing Issue
5.1 Introduction
5.2 Toxicity of Metal Nanoparticles and Influence of Physicochemical Properties
5.2.1 Toxicity of Copper and Copper Oxide Nanoparticles
5.2.2 Toxicity of Gold Nanoparticles
5.2.3 Toxicity of Silver Nanoparticles
5.2.4 Toxicity of Zinc Oxide Nanoparticles
5.2.5 Toxicity of Iron Oxide Nanoparticles
5.2.6 Physicochemical Properties Affecting Toxicity
5.3 Accumulation and Toxicity of Metal-Based Nanoparticles in Various Organs
5.4 Conclusion and Future Perspectives
Acknowledgments
References
Chapter 6 Toxicity, Safety, and Biodistribution of Multifunctional Mesoporous Silica Nanoparticles
6.1 Introduction
6.2 Bioapplicability of Mesoporous Silica Nanoparticles
6.3 Biodistribution, Toxicity, and Safety of MSN
6.3.1 Factors Affecting Biodistribution of Mesoporous Silica Nanoparticles
6.4 Safety Evaluation of Mesoporous Silica Nanoparticles
6.4.1 Cytotoxicity
6.4.2 Tissue Compatibility
6.4.3 Genotoxicity
6.4.4 Immunotoxicity
6.4.5 Autophagy
6.4.6 Endothelial Dysfunction and Toxic Effects on Blood Cells
6.4.7 Blood Compatibility
6.4.8 Neurotoxicity
6.5 Conclusion and Future Directions
References
Chapter 7 Safety and Toxicity issues of Polymeric Nanoparticles: A Serious Concern
7.1 Introduction
7.2 Application of Nanomaterials
7.3 Classification of Nanoparticles (NPs)
7.3.1 Polymeric Nanoparticles
7.4 Nanotoxicology
7.4.1 Toxicity of Nanoparticles
7.4.2 Tissue Toxicity of Nanomedicine
7.4.3 Mechanisms of Nanoparticle Toxicity
7.4.4 Toxicity of Polymeric Nanoparticles
7.4.5 Nanoformulations Showing Toxicity
7.5 Safety Assessment of Nanomedicines by Methodological Considerations
7.5.1 Nanoparticles Safety Study
7.5.2 Methodological Considerations for Safety Assessment of Nanomedicines
7.6 Conclusion and Future Perspectives
References
Chapter 8 Green Synthesis of Copper and Copper-Based Nanoparticles for Their Use in Medicine: Toxicity and Safety
8.1 Introduction
8.2 Green Synthesis Methods of Copper and Copper-Based Nanoparticles
8.2.1 Fungi-Assisted Synthesis of Nanoparticles
8.2.2 Actinomycetes-Assisted Synthesis of Nanoparticles
8.2.3 Bacteria-Assisted Synthesis of Nanoparticles
8.2.4 Algae-Assisted Synthesis of Nanoparticles
8.2.5 Phytochemical-Assisted Synthesis of Nanoparticles
8.2.6 Biomolecule and Biopolymer-Mediated Synthesis of Nanoparticles
8.3 Purification of Copper and Copper-Based Nanoparticles
8.4 Characterization of Green Synthesized Copper and Copper-Based Nanoparticles
8.5 Copper and Copper-Based Nanoparticles as Nanomedicines
8.5.1 Application as Antibacterial Agents
8.5.2 Application as Antifungal Agents
8.5.3 Application as Antiviral Agents
8.5.4 Application as a Targeted Drug Delivery System
8.5.5 Application as Anticancer Agents
8.5.6 Applications in Molecular Imaging
8.6 Copper and Copper-Based Nanoparticles and Their Toxicity
8.6.1 Nanotoxicology
8.6.2 Different Types of Toxicity
8.6.3 Toxicity Effect of Copper and Copper-Based Nanoparticles
8.7 Safety Implications of Copper and Copper-Based Nanoparticles
8.8 Future Perspectives
8.9 Conclusion
References
Part III Nanotoxicology and Drug Delivery
Chapter 9 Gene Delivery Using Nanocarriers: Toxicity and Safety Aspects
9.1 Introduction
9.2 Nanocarrier Types
9.2.1 Lipid-Based Nanocarriers
9.2.2 Polymeric Nanocarriers
9.3 Target Diseases and Routes of Administration
9.4 Learnings from Clinical Trials
9.4.1 Toxicity with Systemic Delivery - Intravenous Administration
9.4.2 Toxicity with Local Delivery
9.5 Mechanisms of Toxicity of Gene Delivery Nanocarriers
9.5.1 Cellular Damage and Inflammatory Mediators
9.5.2 ROS Induction
9.6 Overcoming Toxicity Issues with Nanocarrier-Mediated Gene Therapy
9.6.1 Modification of Genetic Cargoes
9.6.2 Modification of Nanocarrier System
9.6.3 Preclinical Testing for Expected Toxicities
9.7 Future Perspectives and Conclusion
References
Chapter 10 Toxicity and Safety Evaluation of Lipid-Based Nanoparticles for Brain Delivery
10.1 Introduction
10.2 Barriers Across Brain Delivery
10.2.1 The Blood-Brain Barrier (BBB)
10.2.2 The Blood Cerebrospinal Fluid (BCSF) Barrier
10.3 Role of Lipid Nanoparticles in Brain Delivery
10.3.1 Liposomes
10.3.2 Solid Lipid Nanoparticles (SLNs)
10.3.3 Nanostructured Lipid Carriers (NLCs)
10.3.4 Lipid-Drug Conjugates (LDCs)
10.3.5 Lipid Polymer Hybrid Nanoparticles (LPHNPs)
10.4 Transport Mechanisms Involved for Brain Delivery
10.4.1 Paracellular Transport
10.4.2 Transcellular Transport
10.4.3 Carrier-mediated Transport
10.4.4 Receptor-mediated Endocytosis
10.4.5 Adsorptive-mediated Endocytosis
10.5 Toxicity of Lipid Nanoparticles
10.6 Safety of Lipid Nanoparticles
10.7 Conclusion and Future Perspectives
References
Chapter 11 Risk Assessment of Injectable Nanoparticles Used as Nanomedicine
11.1 Introduction
11.2 Nanomaterials, Nanoparticles, and Nanoformulation
11.3 Injectable Nanoparticles Toxicity
11.4 Safety of Nanoparticles in Acute and Chronic Studies
11.5 Future Perspectives and Conclusion
References
Chapter 12 Dermatological Delivery of Nanodrugs: Applications, Toxicity, and Safety
12.1 Introduction
12.2 An Overview of Dermatology and Nanodrugs
12.3 Nanomaterials for Dermatologically Active Nanodrugs
12.4 Nanoformulations for Topical and Transdermal Delivery
12.5 Applications of Dermatological Nanodrugs and Its Delivery Mechanisms
12.5.1 Prevention
12.5.2 Diagnosis
12.5.3 Therapeutic Applications
12.6 Toxicity Evaluation of Dermatologically Active Nanodrugs
12.6.1 Nanodrugs and Toxicity Due to Penetration
12.6.2 Genotoxicity
12.7 Safety Considerations
12.8 Limitations and Risk
12.9 Conclusion
References
Chapter 13 Nanonutraceuticals: Considerations for Toxicity and Safety Assessment
13.1 Introduction
13.2 Novel Carrier-Based Drug Delivery Systems
13.2.1 Lipidic Nanosystems
13.2.2 Polymeric Nanosystems
13.2.3 Lipid Polymer Nanosystems
13.3 Safety and Toxicity Assessment of Nanoparticles
13.4 Approaches for Biodegradable Nanoparticles
13.5 Modified Nanocarriers (Nanosponges)
13.5.1 Cyclodextrin-Based Nanosponges
13.6 Conclusion and Future Perspectives
References
Chapter 14 Current Challenges and Future Needs for Nanotoxicity and Nanosafety Assessment
14.1 Introduction
14.2 Nanomaterials: Risk Assessment
14.3 The Hurdles in Toxicity Evaluation of Nanomaterials
14.3.1 Physicochemical Properties of Nanomaterials' Characterization
14.3.2 In vitro, In vivo, and In silico Approaches for the Assessment of Toxicity for the Nanomaterials
14.4 Nanosafety Assessment Tools
14.5 Conclusion and Perspectives
References
Part IV Nanotechnology, Ethics, and Regulatory Framework
Chapter 15 Safety Regulations for the Use of Nanotechnological Products for Biomedical Applications: A Systematic Literature Review
15.1 Introduction
15.2 The State-of-the-art of Biomedical Applications of Nano-Products
15.3 The Scientific Perspective on Nano-products for Biomedical Applications, Risks, and Regulations
15.4 Using RRI as a Methodological Pathway Toward Communication Between the Science System and the Law System
15.5 Final Considerations and New Propositions
Notes
References
Chapter 16 Nanoethics and Nanotechnology
16.1 Introduction
16.1.1 Types of Nanotechnology
16.1.2 Applications of Nanotechnology
16.2 Nanoethics
16.2.1 Regulatory Agencies
16.2.2 Distributive Justice
16.2.3 Nanoweapons
16.2.4 Ethics in Nanomedicine
16.2.5 Privacy and Confidentiality
16.2.6 Human Enhancement
16.2.7 Nanopollution
16.2.8 Educational Issues
16.2.9 Biological Issues
16.3 Conclusion
References
Chapter 17 Current Regulatory Framework in Nanotechnology and Medicine
17.1 Introduction
17.1.1 Classification of Nanomaterials
17.1.2 Nanoparticles
17.2 Quality Attributes and Regulatory Concerns of Nanomaterials
17.2.1 Physicochemical Characterization
17.2.2 Nonclinical Studies for Nanomaterials
17.2.3 Clinical Studies for Nanomaterials
17.2.4 Identification of Hazardous Material
17.2.5 Exposure Risk to Humans and Environment During Nanomaterial Manufacturing, Storage, or Disposal
17.3 Quality Assessment of Nanomedicines
17.4 Current Regulatory Framework over Nanomaterials
17.4.1 USA
17.4.2 European Union
17.4.3 Taiwan
17.4.4 Iran
17.4.5 Canada
17.4.6 Australia
17.4.7 Japan
17.4.8 India
17.4.9 People's Republic of China
17.4.10 Republic of Korea
17.4.11 Russia
17.4.12 WHO
17.4.13 OECD
17.4.14 ISO
17.4.15 VAMAS
17.5 Conclusion and Future Outlook
References
Index
EULA

Systemvoraussetzungen

Als PDF speichern Als Link merken